Delivery Order SPE2DB25D3404-SPE2DB25FUPNW
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ocrevus 300 mg/10 mL vials, a pharmaceutical product used to treat multiple sclerosis. This firm fixed-price delivery order, valued at $64,452.33, is scheduled for completion by September 3, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract was awarded without a set-aside designation through competitive procurement, reflecting...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency Medical Supply Chain for the supply of Ocrevus 300 mg/10 mL vials. The contract is valued at $120,192.80 under a firm fixed-price arrangement with an ultimate completion date of August 25, 2025. This non-competitive delivery order was issued as a child contract against a larger vehicle, leveraging AmerisourceBergen's established relationship with federal medical procurement. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ocrevus 300 mg/10 mL vials, a specialty pharmaceutical product used in the treatment of multiple sclerosis. This firm fixed-price delivery order, valued at $120,192.80, is set to be completed by August 13, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $36,057.84 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, will fulfill this order as part of its ongoing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a $45,237 delivery order to Amerisourcebergen Drug Corporation for Ocrevus 300 MG/10 ML vials. The firm fixed price order is valued at forty-five thousand two hundred thirty-seven dollars and will be performed in Conshohocken, Pennsylvania under the agency's Pharmaceutical Prime Vendor contract vehicle from August 3rd to August 24th, 2023. Amerisourcebergen will supply the multiple sclerosis treatment to the DLA, which manages the Department of Defense's...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUPNWDelivery Order
The Defense Logistics Agency awarded a $12,019.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for 300 mg/10 mL vials of Ocrevus, a specialty pharmaceutical used to treat multiple sclerosis and other autoimmune conditions. The contract, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, was competitively awarded with no set-aside designation. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a prime pharmaceutical vendor to the Defense Logistics Agency, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military healthcare systems and other federal medical procurement needs. The company's established role as a critical pharmaceutical distributor within the federal supply chain demonstrates its capability to fulfill specialized medication requirements for defense and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 8/1/25 |